脑心通胶囊辅助治疗不稳定型心绞痛的临床疗效和安全性的Meta分析

目的：系统评价脑心通胶囊辅助治疗不稳定型心绞痛的临床疗效及其安全性。方法：计算机检索PubMed（1966-2012．3）、EMbase（1974-2012.3）、CochraneLibrary（2012年第3期）、CBM（1978-2012．3）、CNKI（1994-2012．3）、VIP（1989-2012．3）。纳入脑心通胶囊联合常规药物治疗不稳定型心绞痛的随机对照试验（RCT），并补充检索纳入研究的参考文献；按Cochrane系统评价方法对纳入研究进行资料提取及质量评估后，采用RevMan5．1软件进行统计学分析。结果：共纳入11个RCT，包括共1384例患者，Meta分析结果显示：与常规药物治疗相比，脑心通胶囊联合常规药物明显缓解不稳定型心绞痛患者的临床症状，差异有统计学意义RR=1．24，95％CI（1．18-1．31），P〈0．01]，提高了心电图的改善率RR=1．35，95％CI（1．24-1．47），P〈0．01]。结论：目前研究表明脑心通胶囊辅助治疗不稳定型心绞痛的短期疗效明显优于常规治疗，但其不良反应和远期疗效尚不确定，需要更多高质量随机对照试验进一步证实。

The Clinical Curative Effect and Safety of Naoxintong Capsules in the Treatment of Unstable Angina： A Meta-analysis

Objective： To review the clinical curative effect and safety of Naoxintong Capsules in the treatment of patients with Unstable Angina. Methods： PubMed（1966-2012.3）, EMbase （1974-2012.3）, Cochrane Library（Issue3,2012）, CBM（1978-2012.3）, CNKI （1994-2012.3）, VIP （1989-2012.3） were electronically searched. Randomized controlled trials （RCTs） about Naoxintong Capsules plus conventional drugs in the treatment of Unstable Angina were included, and the relevant references of the included papers were also manually searched. Study selection and analysis were undertaken according to the Cochrane Handbook, and RevMan 5.1 was applied for statistical analyses. Results： Eleven RCTs involving 1384 patients with Unstable Angina were included. The results of meta-analysis showed that the improvement of symptoms RR=l.24, 95%CI （1.18-1.31）,P〈0.01], the improve ofECG RR=l.35, 95%CI（1.24-1.47）, P〈0.01] were superior in the combination arm to the conventional drugs alone arm. Conclusion： The current evidence available showed that the combination of Naoxintong Capsules and conventional drugs may significantly improve the short-term efficacy comparing with conventional drugs alone. However, long-term efficacy and adverse events were not clear yet; more high-quality RCTs should be conducted.